Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Papakostas TD, Lim L, van Zyl T, Miller JB, Modjtahedi BS, Andreoli CM et al. Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab. Eye (Lond) 2015; 30: 79–84.
Epstein DL, Algvere PV, van Wendt G, Seregard S, Kvanta A . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. Ophthalmology 2012; 119 (12): 2587–2591.
Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011; 118 (10): 2041–2049.
Călugăru D, Călugăru M . Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusion: three-year results of a prospective clinical study. J Ocul Pharmacol Ther 2015; 31 (2): 78–86.
Călugăru D, Călugăru M . Intravitreal aflibercept of macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am J Ophthalmol 2015; 159 (3): 607–608.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Authors contribution
DC and MC were involved in design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.
Rights and permissions
About this article
Cite this article
Călugăru, D., Călugăru, M. Comment on: ‘Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab’. Eye 30, 766 (2016). https://doi.org/10.1038/eye.2016.2
Published:
Issue date:
DOI: https://doi.org/10.1038/eye.2016.2
This article is cited by
-
Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion
Graefe's Archive for Clinical and Experimental Ophthalmology (2017)
-
Reply to ‘Comment on: Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizmab’
Eye (2016)
